Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreLeveraging the power of the IQVIA CORE, we support Canada’s pharmaceutical manufacturers as they invest in, and advance, human health. We do this via breakthroughs in insights, technology, analytics and human intelligence that bring the progress in data science together with the possibilities of human science.
Learn MoreHospitals and healthcare providers are looking for cutting-edge decision support to augment their strategy and performance so they can focus on delivering high quality value to patients. As the Human Data Science Company, IQVIA is uniquely positioned to provide actionable data, innovative technology, and expertise customized to the hospital and provider community.
Learn MoreA specialized division of IQVIA (Canada), Health Industry Information Services (HIIS) serves the precise needs of non-pharmaceutical healthcare stakeholders including Retail Pharmacy, Independent Pharmacy, and Specialty Pharmacy.
Learn MoreAlmost everything we do is powered by the IQVIA CORE. This holistic approach allows us to use Human Data Science to create integrated solutions for our customers.
Learn MoreHealth benefit analytics for effective response to market changes.
Learn MoreTake your research further. Data assets that allow you to explore new areas in inquiry that can advance public health efforts. IQVIA supports the Canadian research community and has responded to hundreds of requests to support new areas of inquiry.
Learn MoreExplore our library of resources spanning the healthcare ecosystem. Hear from IQVIA data scientists, doctors, researchers, and other experts on the topics, trends, and market developments that matter to you.
Learn MoreMedia representatives and other industry stakeholders can access current and historical top-line Canada and global pharmaceutical trends for use in story development or vital health research.
Learn MoreWhy work at IQVIA Canada? Help create a healthier world; start right here where we offer a diversity of opportunities.
DISCOVER CAREERSOur passion to make an impact is fueled by the people we work with, a curiosity to bring new ideas to life, and a focus on always doing better.
LEARN MORE"Join IQVIA and see where your skills and competencies can take you.
APPLY NOW11:30 AM - 2:30 PM
Mississauga Convention Centre
Toronto, ON, Canada
11:30 AM - 2:30 PM
Crowne Plaza Montreal Airport
Montreal, QC, Canada
Please note: This event is open only to PharmaFocus Subscribers. If you are unsure if your company subscribes to PharmaFocus, please contact raquel.bowes@iqvia.com.
In the increasingly challenging pharmaceutical business environment, knowing what's ahead is key to your company's ongoing success.
Mark Omoto, GM, IQVIA, Marketing & Corporate Communications, will present an update on the current market issues that have shaped the industry since the spring PharmaFocus 2023 Industry Briefing. Hear the latest on pharmaceutical market performance, new product launch performance, and the Canadian industry forecast update and the key assumptions that are shaping it.
AND, on the same program…
Joan McCormick, Principal, CES Resources, IQVIA, will provide insights and guidance on the latest information available regarding the PMPRB and new patented medicine pricing regulations, which are set to take effect July 1, 2020 and which will have far-reaching implications for both brand and generic manufacturers, among others.
During this interactive presentation, PharmaFocus 2023 Update co-authors Gerry Jeffcott and Bill Dempster will provide a roundup of the significant political, policy and health system developments that have occurred in the six months since the April PharmaFocus industry briefing along with their perspectives on the market implications of these changes.